y guided to a ligh= Q3 and announced it is pushing forward its R&D spend to advance its t=st menu in oncology testing (breast, leukemia, bladder)." GenMark's share-price drop came without any obvious ca=alysts, just as its 23 percent increase in share price in June had no appa=ent drivers. Its stock ste